Abstract
Fructose-1,6-bisphosphatase (FBP1), the rate-limiting enzyme in gluconeogenesis, is reduced in expression in certain cancers where it has been hypothesized to act as a tumor suppressor, including in hepatocellular carcinoma (HCC). Here, we report functional evidence supporting this hypothesis, providing a preclinical rationale to develop FBP1 as a therapeutic target for HCC treatment. Three independent cohorts totaling 594 cases of HCC were analyzed to address clinical significance. Lower FBP1 expression associated with advanced tumor stage, poor overall survival, and higher tumor recurrence rates. In HCC cell lines, where endogenous FBP1 expression is low, engineering its ectopic over-expression inhibited tumor growth and intracellular glucose uptake by reducing aerobic glycolysis. In patient specimens, promoter methylation and copy-number loss of FBP1 were independently associated with decreased FBP1 expression. Similarly, FBP1 downregulation in HCC cell lines was also associated with copy-number loss. HCC specimens exhibiting low expression of FBP1 had a highly malignant phenotype, including large tumor size, poor differentiation, impaired gluconeogenesis, and enhanced aerobic glycolysis. The effects of FBP1 expression on prognosis and glucose metabolism were confirmed by gene set enrichment analysis. Overall, our findings established that FBP1 downregulation in HCC contributed to tumor progression and poor prognosis by altering glucose metabolism, and they rationalize further study of FBP1 as a prognostic biomarker and therapeutic target in HCC patients.
| Original language | English |
|---|---|
| Pages (from-to) | 3265-3276 |
| Number of pages | 12 |
| Journal | Cancer Research |
| Volume | 76 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Jun 1 2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma. / Hirata, Hidenari; Sugimachi, Keishi; Komatsu, Hisateru; Ueda, Masami; Masuda, Takaaki; Uchi, Ryutaro; Sakimura, Shotaro; Nambara, Sho; Saito, Tomoko; Shinden, Yoshiaki; Iguchi, Tomohiro; Eguchi, Hidetoshi; Ito, Shuhei; Terashima, Kotaro; Sakamoto, Katsumi; Hirakawa, Masakazu; Honda, Hiroshi; Mimori, Koshi.
In: Cancer Research, Vol. 76, No. 11, 01.06.2016, p. 3265-3276.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma
AU - Hirata, Hidenari
AU - Sugimachi, Keishi
AU - Komatsu, Hisateru
AU - Ueda, Masami
AU - Masuda, Takaaki
AU - Uchi, Ryutaro
AU - Sakimura, Shotaro
AU - Nambara, Sho
AU - Saito, Tomoko
AU - Shinden, Yoshiaki
AU - Iguchi, Tomohiro
AU - Eguchi, Hidetoshi
AU - Ito, Shuhei
AU - Terashima, Kotaro
AU - Sakamoto, Katsumi
AU - Hirakawa, Masakazu
AU - Honda, Hiroshi
AU - Mimori, Koshi
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Fructose-1,6-bisphosphatase (FBP1), the rate-limiting enzyme in gluconeogenesis, is reduced in expression in certain cancers where it has been hypothesized to act as a tumor suppressor, including in hepatocellular carcinoma (HCC). Here, we report functional evidence supporting this hypothesis, providing a preclinical rationale to develop FBP1 as a therapeutic target for HCC treatment. Three independent cohorts totaling 594 cases of HCC were analyzed to address clinical significance. Lower FBP1 expression associated with advanced tumor stage, poor overall survival, and higher tumor recurrence rates. In HCC cell lines, where endogenous FBP1 expression is low, engineering its ectopic over-expression inhibited tumor growth and intracellular glucose uptake by reducing aerobic glycolysis. In patient specimens, promoter methylation and copy-number loss of FBP1 were independently associated with decreased FBP1 expression. Similarly, FBP1 downregulation in HCC cell lines was also associated with copy-number loss. HCC specimens exhibiting low expression of FBP1 had a highly malignant phenotype, including large tumor size, poor differentiation, impaired gluconeogenesis, and enhanced aerobic glycolysis. The effects of FBP1 expression on prognosis and glucose metabolism were confirmed by gene set enrichment analysis. Overall, our findings established that FBP1 downregulation in HCC contributed to tumor progression and poor prognosis by altering glucose metabolism, and they rationalize further study of FBP1 as a prognostic biomarker and therapeutic target in HCC patients.
AB - Fructose-1,6-bisphosphatase (FBP1), the rate-limiting enzyme in gluconeogenesis, is reduced in expression in certain cancers where it has been hypothesized to act as a tumor suppressor, including in hepatocellular carcinoma (HCC). Here, we report functional evidence supporting this hypothesis, providing a preclinical rationale to develop FBP1 as a therapeutic target for HCC treatment. Three independent cohorts totaling 594 cases of HCC were analyzed to address clinical significance. Lower FBP1 expression associated with advanced tumor stage, poor overall survival, and higher tumor recurrence rates. In HCC cell lines, where endogenous FBP1 expression is low, engineering its ectopic over-expression inhibited tumor growth and intracellular glucose uptake by reducing aerobic glycolysis. In patient specimens, promoter methylation and copy-number loss of FBP1 were independently associated with decreased FBP1 expression. Similarly, FBP1 downregulation in HCC cell lines was also associated with copy-number loss. HCC specimens exhibiting low expression of FBP1 had a highly malignant phenotype, including large tumor size, poor differentiation, impaired gluconeogenesis, and enhanced aerobic glycolysis. The effects of FBP1 expression on prognosis and glucose metabolism were confirmed by gene set enrichment analysis. Overall, our findings established that FBP1 downregulation in HCC contributed to tumor progression and poor prognosis by altering glucose metabolism, and they rationalize further study of FBP1 as a prognostic biomarker and therapeutic target in HCC patients.
UR - http://www.scopus.com/inward/record.url?scp=84975038089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975038089&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-15-2601
DO - 10.1158/0008-5472.CAN-15-2601
M3 - Article
C2 - 27197151
AN - SCOPUS:84975038089
VL - 76
SP - 3265
EP - 3276
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 11
ER -